This page lists international publications related to CA17140 which acknowledge the Action but cannot be classified as Action papers
- Andonovic V, Dimitrov AT, Paunovic P, Andonovic B. Determination of the molecular structure and (m,n) index assignment to the constituent walls of MWCNTs with undetermined diameters and chirality. Beilstein Arch. 2020, 2020 132 (OA)
- Andonovik B, Andova V, Atanasova Pacemska T, Paunovic P, Andonovic V, Djordjevic J, Dimitrov, A. Distance based topological indices on multiwall carbon nanotubes samples obtaiend by electrolysis in molten salts. Balkan Journal of Applied Mathematics and Informatics. 2020;3(1):7-12 (OA)
- Lopes-Nunes J, Lifante J, Shen Y, Ximendes EC, Jaque D, Iglesias-de la Cruz MC, Cruz C. Biological studies of an ICG-tagged aptamer as drug delivery system for malignant melanoma. Eur J Pharm Biopharm. 2020;154:228-235. Copyright (C) Elsevier B.V. (https://doi.org/10.1016/j.ejpb.2020.07.018).
- Garofalo, M.; Staniszewska, M.; Salmaso, S.; Caliceti, P.; Pancer, K.W.; Wieczorek, M.; Kuryk, L. Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2. Vaccines 2020, 8, 293. (OA)
- Kohl Y, Biehl M, Spring S, Hesler M, Ogourtsov V, Todorovic M, Owen J, Elje E, Kopecka K, Moriones OH, Bastús NG, Simon P, Dubaj T, Rundén-Pran E, Puntes V, William N, von Briesen H, Wagner S, Kapur N, Mariussen E, Nelson A, Gabelova A, Dusinska M, Velten T, Knoll T. Microfluidic In Vitro Platform for (Nano)Safety and (Nano)Drug Efficiency Screening. Small. 2021;17(15):e2006012. (OA)
-
Giesen B, Nickel AC, Barthel J, Kahlert UD, Janiak C. Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery. Pharmaceutics. 2021;13:295 (https://doi.org/10.3390/pharmaceutics13020295)
- Tiwari AP, Thorat ND, Pricl S, Patil RM, Rohiwal S, Townley H. Bioink: a 3D-bioprinting tool for anticancer drug discovery and cancer management. Drug Discov Today. 2021;26(7):1574-1590. Copyright (C) Elsevier B.V. (https://doi.org/10.1016/j.drudis.2021.03.010).
- Khot VM, Salunkhe AB, Pricl S, Bauer J, Thorat ND, Townley H. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. Drug Discov Today. 2021;26(3):724-739 Copyright (C) Elsevier B.V. (https://doi.org/110.1016/j.drudis.2020.12.016)
- Aulic S, Marson D, Laurini E, Skoko N, Fermeglia M, Pricl S. Regulatory, safety, and toxicological concerns of nanomaterials with their manufacturing issues. In Nano-pharmacokinetics and theranostics: advancing cancer therapy, Nanasaheb D. Thorat and Nitesh Kumar Editors, Academic Press. Chapter 16, pp. 93-115 (2021). Copyright (C) 2020 Elsevier B.V.
- Oddone N, Boury F, Garcion E, Grabrucker AM, Martinez MC, Da Ros F, Janaszewska A, Forni F, Vandelli MA, Tosi G, Ruozi B, Duskey JT. Synthesis, characterization, and in vitro studies of an reactive oxygen species (ROS)-responsive methoxy polyethylene glycol-thioketal-melphalan prodrug for glioblastoma treatment. Front Pharmacol. 2020;11:574 (OA)
-
Garaiova Z, Melikishvili S, Michlewska S, Ionov M, Pedziwiatr-Werbicka E, Waczulikova I, Hianik T, Gomez-Ramirez R, de la Mata FJ, Bryszewska M. Dendronized gold nanoparticles as carriers for gp160 (HIV-1) peptides: biophysical insight into complex formation. Langmuir. 2021;37(4):1542-1550. Copyright (C) 2021 The American Chemical Society (https://doi.org/10.1021/acs.langmuir.0c03159)
- Fernandes AR, Lima JC, Rodríguez L. Aggregation versus biological activity in Gold(I) complexes. An unexplored concept. Inorg Chem. 2021;60(24):18753-18763. Copyright (C) 2021 The American Chemical Society (https://doi.org/10.1021/acs.inorgchem.1c02359)
- Rosental M, Coldman RN, Moro AJ, Angurell I, Gomila RM, Frontera A, Lima JC, Rodríguez L. Using room temperature phosphorescence of Gold(I) complexes for PAHs sensing. Molecules. 2021;26(9):2444 (OA)
- Fernández-Bertólez N, Brandão F, Costa C, Pásaro E, Teixeira JP, Laffon B, Valdiglesias V. Suitability of the In Vitro Cytokinesis-Block Micronucleus Test for Genotoxicity Assessment of TiO2 Nanoparticles on SH-SY5Y Cells. Int J Mol Sci. 2021 22(16):8558 (OA)
- Valdiglesias V, Fernández-Bertólez N, Lema-Arranz C, Rodríguez-Fernández R, Pásaro E, Reis AT, Teixeira JP, Costa C, Laffon B. Salivary Leucocytes as In Vitro Model to Evaluate Nanoparticle-Induced DNA Damage. Nanomaterials (Basel). 2021;11(8):1930 (OA)
- Kuzminac I, Ćelić A, Bekić S, Kojić V, Savić M, Ignjatović N. Hormone receptor binding, selectivity and cytotoxicity of steroid D-homo lactone loaded chitosan nanoparticles for the treatment of breast and prostate cancer cells. Colloids and Surfaces B: Biointerfaces, 2022, 112597 (https://doi.org/10.1016/j.colsurfb.2022.112597).
- Dhumal D, Maron B, Malach E, Lyu Z, Ding L, Marson D, Laurini E, Tintaru A, Ralahy B, Giorgio S, Pricl S, Hayouka Z, Peng L. Dynamic self-assembling supramolecular dendrimer nanosystems as potent antibacterial candidates against drug-resistant bacteria and biofilms. Nanoscale. 2022 Jun 1. doi: 10.1039/d2nr02305a. Epub ahead of print (OA)
- Aulic S, Marson D, Laurini E, Fermeglia M, Pricl S. Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. In Nanomedicines for Breast Cancer Theranostics, Nanasaheb D. Thorat and Joanna Bauer Editors, Elsevier Inc. Chapter 16, pp. 395-404 (2020). Copyright (C) 2020 Elsevier B.V
- Shen Y, Lifante J, Zabala-Gutierrez I, de la Fuente-Fernández M, Granado M, Fernández N, Rubio-Retama J, Jaque D, Marin R, Ximendes E, Benayas A. Reliable and remote monitoring of absolute temperature during liver inflammation via luminescence-lifetime-based nanothermometry. Adv Mater. 2022 Feb;34(7):e2107764 (OA).
IMPORTANT NOTICE: CA17140 publications must report the following official sentence in the acknowledgment section:
This article/publication is based upon work from COST Action CA 17140 "Cancer Nanomedicine from the Bench to the Bedside" supported by COST (European Cooperation in Science and Technology).
All applicants must carefully read the funding rules detailed on the COST website and acknowledge COST as a funding source. The acknowledgment shall follow the COST guidelines on visual identity.
Visual identity - COST – available here
